How Long Do You Take PARP Inhibitors for Ovarian Cancer?

The length of time you take a PARP inhibitor for ovarian cancer maintenance therapy depends primarily on whether you are taking it after your initial (frontline) chemotherapy or for recurrent disease. For frontline maintenance, treatment is typically given for a set duration, such as 2 years for olaparib ^[1] or up to 3 years for niraparib ^[2][3]. If you are taking a PARP inhibitor for recurrent ovarian cancer, the medication is generally continued indefinitely as long as it is working and you can tolerate the side effects, though recent guidelines restrict this primarily to patients with certain genetic profiles ^[4][5].

Frontline Maintenance: Set Timelines

When you are first diagnosed with advanced ovarian cancer and respond to initial platinum-based chemotherapy (drugs like carboplatin or cisplatin), PARP inhibitors are used to delay or prevent the cancer from returning. In this “frontline” setting, the duration of therapy is usually capped:

• Olaparib (Lynparza): Typically taken for up to 2 years for patients with a BRCA mutation. It is also prescribed for patients with HRD-positive tumors (often in combination with another drug called bevacizumab). Studies have shown that a 2-year course provides long-lasting benefits that continue even after you stop taking the drug ^[1].
• Niraparib (Zejula): Typically taken for up to 3 years. It can be prescribed regardless of your BRCA mutation status ^[2][3].

Your doctor will usually stop the medication once you reach these milestones, provided the cancer has not returned. If your cancer does start to grow again while on the drug, your care team will transition you to a different treatment ^[2].

Recurrent Setting: Treating Until Progression

If your ovarian cancer has returned (recurred) and you have had a good response to another round of platinum-based chemotherapy, PARP inhibitors are used as a long-term maintenance strategy. While historically used more broadly, recent updates mean these drugs are now typically restricted to patients with specific genetic profiles, such as a BRCA mutation. In this situation, medications like olaparib, niraparib, or rucaparib (Rubraca) are generally taken indefinitely ^[5][6].

“Indefinitely” means you will continue taking the daily pills until one of two things happens:

1. Disease progression: The cancer begins to grow again, in which case you will switch to a different therapy ^[4].
2. Unacceptable side effects: The toxicities of the medication become too difficult to manage safely, even after trying dose reductions or breaks ^[7].

Managing Daily Side Effects

Because PARP inhibitors are taken for years at a time, managing how they impact your daily life is a major focus of your care. While these drugs are often well-tolerated, they do have a distinct side effect profile ^[8].

Physical Symptoms
Most patients will experience some degree of fatigue, nausea, diarrhea, constipation, and changes in taste ^[9]. These symptoms are often most noticeable in the first few months and can frequently be managed with supportive medications and lifestyle adjustments—such as eating smaller, more frequent meals, or altering when you take your pills to sleep through the worst nausea ^[10].

Blood Counts and Bone Marrow Effects
PARP inhibitors can suppress your bone marrow, leading to lower levels of blood cells. This is called hematologic toxicity and is a primary concern for long-term use ^[9][7].

• Anemia (low red blood cells, causing severe fatigue) is a very common reason for needing dose adjustments, particularly with olaparib ^[11].
• Thrombocytopenia (low platelets, which help blood clot) is notably more common with niraparib ^[11][5].
• Neutropenia (low white blood cells, increasing your risk of infection) can also occur, especially in older patients ^[12]. Seek immediate medical attention if you develop a fever, as this can be a sign of a dangerous infection when your white blood cell count is low.

To monitor these risks, your care team will check your blood counts very frequently—often weekly or bi-weekly—during the first 1 to 3 months of treatment ^[10]. After this initial period, blood tests will be spaced out (typically once a month) but remain a regular part of your routine.

If your blood counts drop too low, your doctor will likely pause the medication until your body recovers, and then restart it at a lower dose. These dose interruptions and reductions are incredibly common, expected, and allow you to stay on the medication safely long-term ^[7][5].

While rare, long-term use of PARP inhibitors carries a small risk of developing serious blood cancers, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) ^[1][5]. Your doctor will continue to monitor your blood counts for any signs of these conditions.